Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study
Randomised controlled trialHumansWith zinc (as polaprezinc / zinc-L-carnosine)
This study tested carnosine together with zinc (as polaprezinc / zinc-L-carnosine). Its results cannot be assigned to carnosine alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 20 patients on long-term low-dose aspirin with small-bowel injury on capsule endoscopy
- Dose used in the study
- 150 mg polaprezinc per day
- Duration
- 4 weeks
- What was measured
- Number and type of small-bowel mucosal lesions (reddened lesions, erosions, ulcers) on capsule endoscopy before and after 4 weeks.
What the authors reported
The median number of reddened lesions and erosions or ulcers fell significantly in the polaprezinc group (p < 0.05). There was no significant change in the control group, which received no treatment. The authors said polaprezinc may be effective against this type of injury.
Limits of this study
Pilot study, 20 patients. Control group received no treatment, so not blinded. Four weeks. Between-group difference not reported in the abstract. Full text not read.
Source
PubMed 23826914 · doi:10.1186/1471-230X-13-108
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.